The $2.40 central target is the arithmetic mean of four individually verified analyst price targets. B. Riley Securities holds the most cautious view at $1.20 (Hold, November 9, 2026), while TD Cowen set a $2.00 target (Buy) and Roth MKM a $2.50 target (Buy), both in August 2026. Truist Financial carries the highest target at $4.00 (Buy), reiterated in November 2026. The mean of these four figures is about $2.43, rounded to $2.40; the low-to-high range of $1.20 to $4.00 is unusually wide, a sign of uncertainty rather than conviction. Aggregator S&P Global reports a "Strong Buy" rating across five analysts, though the divergence between a $1.20 Hold and a $4.00 Buy underscores that the Street is split on how quickly biote Corp. (BTMD) can restore growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of mid-November 2026, shares traded near $0.81, toward the bottom of a 52-week range of roughly $0.81 to $2.90. Reaching $2.40 would require a gain of about 196%, which must be described as a very large move. The path toward that level would almost certainly depend on a sustained operational recovery: a return to revenue growth, a rebuild of the commercial organization, and a transition back to profitability after a 2026 in which revenue declined and the company posted a net loss over the first nine months. Because the stock now carries a market capitalization of only roughly $26 million and a forward P/E near 6x, even modest improvements in fundamentals could move the shares sharply in either direction. From what I see, this low valuation creates both opportunity and risk.
Several factors could underpin a recovery. Truist has pointed to improving procedure activity, a stabilizing clinic-cancellation rate, and the expected margin benefit from bringing pellet manufacturing in-house as early signs that biote Corp. (BTMD) is working through the operational disruption of the first half of 2026. Management maintained full-year 2026 revenue guidance above $175 million despite a 9.6% year-over-year third-quarter revenue decline, and gross margin remained solid at 67.7% in the quarter. A deeply discounted valuation and a balance-sheet position that lets the company continue its restructuring also give the shares room to re-rate if execution improves and analysts begin revising estimates higher.
The obstacles are substantial. Third-quarter 2026 revenue of $43.3 million fell short of estimates, and the company reported diluted EPS of just $0.01. Revenue contracted in the wake of a January 2026 product recall, and new customer additions remained below normal levels entering the fourth quarter. For the first nine months of 2026, biote Corp. (BTMD) posted a net loss of $3.9 million versus a $25.1 million profit a year earlier. A market capitalization in the tens of millions, a beta near 1.7, and an interim chief executive (Robert Peterson, who also serves as CFO) all add execution and governance uncertainty that could keep a discount embedded in the shares.
From a technical standpoint, biote Corp. (BTMD) is trading at multi-year lows. The $0.80-to-$0.81 area represents a crucial support level that has held so far, while the psychologically important $1.00 mark and the prior $1.20-to-$1.50 zone act as nearer-term resistance levels on any recovery. The 52-week high near $2.90 is the most durable overhead level on the chart and sits just above the central $2.40 target, meaning the shares would need to clear several layers of selling pressure before that objective becomes relevant. I’m watching this closely with an eye on how volume develops at these levels.
Analyst price targets generally reflect a roughly 12-month research horizon, though the specific time frame varies by firm and by the assumptions each embeds. Investors should watch upcoming quarterly results and guidance, evidence that procedure volumes and clinic retention are stabilizing, progress in adding new practitioners, and any analyst revisions to revenue or margin estimates. The fourth-quarter 2026 report will be especially important because management has signaled it does not yet point to a clear return to growth.
In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. These tools use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like biote Corp. (BTMD), this kind of automated screening can help surface opportunities, track existing positions, and identify trend shifts more efficiently than manual review alone. Traders can explore these signals as one input alongside their own research.
Can biote Corp. (BTMD) reach $2.40? The target is a real, calculated figure — the mean of four current analyst price targets — but it sits far above a stock that has been cut down by a product recall, a restructuring, and falling revenue. The bullish case rests on a low valuation, stabilizing operations, and margin recovery, while the bearish case points to persistent revenue declines and a thin profitability cushion. The exceptionally wide $1.20-to-$4.00 analyst range is a reminder that this is a high-uncertainty, high-volatility situation. Reaching $2.40 would demand a near-tripling of the share price and would likely require clear, sustained evidence that growth has returned. Investors should treat the target as a directional benchmark, not a forecast, and watch the company's next several quarters closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
BTMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 43 cases where BTMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where BTMD advanced for three days, in 179 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BTMD as a result. In 74 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for BTMD turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BTMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BTMD entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.462) is normal, around the industry mean (204.532). P/E Ratio (5.889) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.243) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. BTMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement